SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-019008
Filing Date
2023-11-14
Accepted
2023-11-14 16:01:25
Documents
79
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nrxp-20230930x10q.htm   iXBRL 10-Q 1711105
2 EX-10.1 nrxp-20230930xex10d1.htm EX-10.1 28779
3 EX-31.1 nrxp-20230930xex31d1.htm EX-31.1 15360
4 EX-31.2 nrxp-20230930xex31d2.htm EX-31.2 15415
5 EX-32.1 nrxp-20230930xex32d1.htm EX-32.1 7096
6 EX-32.2 nrxp-20230930xex32d2.htm EX-32.2 6412
  Complete submission text file 0001558370-23-019008.txt   7852475

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrxp-20230930.xsd EX-101.SCH 72763
8 EX-101.CAL nrxp-20230930_cal.xml EX-101.CAL 36052
9 EX-101.DEF nrxp-20230930_def.xml EX-101.DEF 318592
10 EX-101.LAB nrxp-20230930_lab.xml EX-101.LAB 464432
11 EX-101.PRE nrxp-20230930_pre.xml EX-101.PRE 462169
73 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20230930x10q_htm.xml XML 1202821
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38302 | Film No.: 231405648
SIC: 2834 Pharmaceutical Preparations